International Myeloma Society
United Kingdom
Financial Health Score
9-metric score across financial health, operational efficiency, and organizational resilience. Based on IRS Form 990 data.
Very Good
How This Organization Compares
Compared to 5 peers in Medical Research with $10M-$100M revenue
Working Capital Ratio (net assets ÷ expenses)
Financial Trends
5-Year Trend Analysis
Financial Health Indicators
Filing History
5 filings on record| Year | Revenue | Expenses | Assets | |
|---|---|---|---|---|
| 2023 | $11,428,850↑219% | $9,444,972↑260% | $8,793,580↑6% | |
| 2022 | $3,584,528↓20% | $2,623,443↑43% | $8,333,584↑13% | — |
| 2021 | $4,469,545↑93% | $1,839,048↑1502% | $7,371,497↑56% | — |
| 2020 | $2,311,447↓46% | $114,818↓97% | $4,735,356↑85% | — |
| 2019 | $4,263,040 | $3,409,562 | $2,564,663 | — |
Frequently Asked Questions
What does International Myeloma Society do?▼
International Myeloma Society is a medical research nonprofit organization based in . It is classified under NTEE code H30 and is registered as a 501(c) tax-exempt organization with the IRS.
Is International Myeloma Society financially healthy?▼
Based on our 9-metric Financial Health Score model, International Myeloma Society has a score of 78/100 (Grade: A-). This score evaluates working capital, surplus consistency, debt ratio, revenue trends, program spending, fundraising efficiency, executive compensation, revenue diversification, and vulnerability indicators.
How much revenue does International Myeloma Society generate?▼
International Myeloma Society reports $11.8M in annual revenue and holds $10.8M in total assets, based on IRS filings.
Similar Organizations
Explore more organizations in the Medical Research category.